261 related articles for article (PubMed ID: 29278207)
21. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
Cleland JG; Teerlink JR; Senior R; Nifontov EM; Mc Murray JJ; Lang CC; Tsyrlin VA; Greenberg BH; Mayet J; Francis DP; Shaburishvili T; Monaghan M; Saltzberg M; Neyses L; Wasserman SM; Lee JH; Saikali KG; Clarke CP; Goldman JH; Wolff AA; Malik FI
Lancet; 2011 Aug; 378(9792):676-83. PubMed ID: 21856481
[TBL] [Abstract][Full Text] [Related]
22. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Legg JC; Büchele G; Varin C; Kurtz CE; Malik FI; Honarpour N
JACC Heart Fail; 2020 Apr; 8(4):329-340. PubMed ID: 32035892
[TBL] [Abstract][Full Text] [Related]
23. Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K.
Utter MS; Ryba DM; Li BH; Wolska BM; Solaro RJ
J Cardiovasc Pharmacol; 2015 Oct; 66(4):347-53. PubMed ID: 26065842
[TBL] [Abstract][Full Text] [Related]
24. [CLINICAL EFFICACY OF A REPRESENTATIVE OF A NEW CLASS OF INOTROPIC AGENTS - THE DIRECT ACTIVATOR OF MYOSIN OF CARDIOMYOCYTES OMECAMTIV MECARBIL IN HEART FAILURE WITH A REDUCED EJECTION FRACTION].
Kravchenko I; Rudyk I; Medentseva O
Georgian Med News; 2021 Sep; (318):165-171. PubMed ID: 34628401
[TBL] [Abstract][Full Text] [Related]
25. Cardiac myosin activation part 1: from concept to clinic.
Malik FI; Morgan BP
J Mol Cell Cardiol; 2011 Oct; 51(4):454-61. PubMed ID: 21616079
[TBL] [Abstract][Full Text] [Related]
26. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.
Teerlink JR; Felker GM; McMurray JJ; Solomon SD; Adams KF; Cleland JG; Ezekowitz JA; Goudev A; Macdonald P; Metra M; Mitrovic V; Ponikowski P; Serpytis P; Spinar J; Tomcsányi J; Vandekerckhove HJ; Voors AA; Monsalvo ML; Johnston J; Malik FI; Honarpour N;
Lancet; 2016 Dec; 388(10062):2895-2903. PubMed ID: 27914656
[TBL] [Abstract][Full Text] [Related]
27. The energy-saving effect of a new myosin activator, omecamtiv mecarbil, on LV mechanoenergetics in rat hearts with blood-perfused isovolumic contraction model.
Obata K; Morita H; Takaki M
Naunyn Schmiedebergs Arch Pharmacol; 2019 Sep; 392(9):1065-1070. PubMed ID: 31267148
[TBL] [Abstract][Full Text] [Related]
28. Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament.
Kampourakis T; Zhang X; Sun YB; Irving M
J Physiol; 2018 Jan; 596(1):31-46. PubMed ID: 29052230
[TBL] [Abstract][Full Text] [Related]
29. Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.
Kaplinsky E; Mallarkey G
Drugs Context; 2018; 7():212518. PubMed ID: 29707029
[TBL] [Abstract][Full Text] [Related]
30. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
Lewis GD; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Böhm M; Teerlink JR; Docherty KF; Lopes RD; Divanji PH; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Felker GM
JAMA; 2022 Jul; 328(3):259-269. PubMed ID: 35852527
[TBL] [Abstract][Full Text] [Related]
31. A new approach to inotropic therapy in the treatment of heart failure: cardiac myosin activators in treatment of HF.
Garg V; Frishman WH
Cardiol Rev; 2013; 21(3):155-9. PubMed ID: 23018669
[TBL] [Abstract][Full Text] [Related]
32. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Biering-Sørensen T; Böhm M; Bonderman D; Fang JC; Lanfear DE; Lund M; Momomura SI; O'Meara E; Ponikowski P; Spinar J; Flores-Arredondo JH; Claggett BL; Heitner SB; Kupfer S; Abbasi SA; Malik FI;
J Am Coll Cardiol; 2021 Jul; 78(2):97-108. PubMed ID: 34015475
[TBL] [Abstract][Full Text] [Related]
33. Treatments targeting inotropy.
Maack C; Eschenhagen T; Hamdani N; Heinzel FR; Lyon AR; Manstein DJ; Metzger J; Papp Z; Tocchetti CG; Yilmaz MB; Anker SD; Balligand JL; Bauersachs J; Brutsaert D; Carrier L; Chlopicki S; Cleland JG; de Boer RA; Dietl A; Fischmeister R; Harjola VP; Heymans S; Hilfiker-Kleiner D; Holzmeister J; de Keulenaer G; Limongelli G; Linke WA; Lund LH; Masip J; Metra M; Mueller C; Pieske B; Ponikowski P; Ristić A; Ruschitzka F; Seferović PM; Skouri H; Zimmermann WH; Mebazaa A
Eur Heart J; 2019 Nov; 40(44):3626-3644. PubMed ID: 30295807
[TBL] [Abstract][Full Text] [Related]
34. Combined Therapy With Dobutamine and Omecamtiv Mecarbil in Pigs With Ischemic Acute Heart Failure Is Attributed to the Effect of Dobutamine.
Rødland L; Rønning L; Kildal AB; Myrmel T; How OJ
J Cardiovasc Pharmacol Ther; 2020 May; 25(3):232-239. PubMed ID: 31645117
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analyses of the inotropic compound omecamtiv mecarbil in rat and human cardiac preparations.
Rhoden A; Schulze T; Pietsch N; Christ T; Hansen A; Eschenhagen T
Am J Physiol Heart Circ Physiol; 2022 Mar; 322(3):H373-H385. PubMed ID: 35030072
[TBL] [Abstract][Full Text] [Related]
36. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.
Teerlink JR; Felker GM; McMurray JJV; Ponikowski P; Metra M; Filippatos GS; Ezekowitz JA; Dickstein K; Cleland JGF; Kim JB; Lei L; Knusel B; Wolff AA; Malik FI; Wasserman SM;
J Am Coll Cardiol; 2016 Mar; 67(12):1444-1455. PubMed ID: 27012405
[TBL] [Abstract][Full Text] [Related]
37. Omecamtiv mecarbil attenuates length-tension relationship in healthy rat myocardium and preserves it in monocrotaline-induced pulmonary heart failure.
Lookin O; Kuznetsov D; Protsenko Y
Clin Exp Pharmacol Physiol; 2022 Jan; 49(1):84-93. PubMed ID: 34459025
[TBL] [Abstract][Full Text] [Related]
38. Myosin from the ventricle is more sensitive to omecamtiv mecarbil than myosin from the atrium.
Shchepkin DV; Nabiev SR; Nikitina LV; Kochurova AM; Berg VY; Bershitsky SY; Kopylova GV
Biochem Biophys Res Commun; 2020 Aug; 528(4):658-663. PubMed ID: 32513536
[TBL] [Abstract][Full Text] [Related]
39. Cardiac Myosin Activation for the Treatment of Systolic Heart Failure.
Bernier TD; Buckley LF
J Cardiovasc Pharmacol; 2021 Jan; 77(1):4-10. PubMed ID: 33165138
[TBL] [Abstract][Full Text] [Related]
40. Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study.
Felker GM; Solomon SD; Metra M; Mcmurray JJV; Diaz R; Claggett B; Lanfear DE; Vandekerckhove H; Biering-Sørensen T; Lopes RD; Arias-Mendoza A; Momomura SI; Corbalan R; Ramires FJA; Zannad F; Heitner SB; Divanji PH; Kupfer S; Malik FI; Teerlink JR
J Card Fail; 2024 Jun; 30(6):755-763. PubMed ID: 38215932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
